Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma
- PMID: 1796397
Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma
Abstract
An increasing amount of evidence suggests that coagulation factors VIII and IX play a role not only in the intrinsic but also in the extrinsic pathway of coagulation. In this context the influence of the Extrinsic Pathway Inhibitor (EPI) on the coagulation time of hemophilia plasma lacking FVIII or FIX has been investigated. The coagulation time was measured in a dilute thromboplastin assay. Addition of recombinant EPI (rEPI) prolonged the coagulation time of normal plasma while the addition of an inhibitory antibody against EPI shortened the coagulation time. At low concentrations of thromboplastin the coagulation time of hemophilia plasma was prolonged and at all dilutions of thromboplastin, addition of anti-EPI IgG normalized the coagulation time of a hemophilia plasma. Analysis of 10 individual donor plasma samples and 8 individual hemophilia samples showed that addition of anti-EPI IgG shortened the coagulation time more in hemophilia plasma than in normal plasma. This illustrates the importance of a powerful extrinsic FVII dependent pathway to achieve hemostasis in the case of FVIII or FIX deficiency (hemophilia A and B).
Similar articles
-
Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas.Thromb Res. 1991 Oct 15;64(2):213-22. doi: 10.1016/0049-3848(91)90120-l. Thromb Res. 1991. PMID: 1811340
-
The role of factor XI in a dilute thromboplastin assay of extrinsic coagulation pathway.Thromb Haemost. 2001 Jun;85(6):1055-9. Thromb Haemost. 2001. PMID: 11434684
-
The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation.Thromb Haemost. 1991 Jul 12;66(1):6-15. Thromb Haemost. 1991. PMID: 1926052 Review. No abstract available.
-
Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol.Blood Coagul Fibrinolysis. 1991 Jun;2(3):425-33. Blood Coagul Fibrinolysis. 1991. PMID: 1932528
-
Factor VII and haemostasis.Blood Coagul Fibrinolysis. 1990 Jun;1(2):175-81. Blood Coagul Fibrinolysis. 1990. PMID: 2130929 Review.
Cited by
-
Biology of tissue factor pathway inhibitor.Blood. 2014 May 8;123(19):2934-43. doi: 10.1182/blood-2013-11-512764. Epub 2014 Mar 11. Blood. 2014. PMID: 24620349 Free PMC article. Review.
-
Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data.Haemophilia. 2019 Jan;25(1):60-66. doi: 10.1111/hae.13627. Epub 2018 Nov 8. Haemophilia. 2019. PMID: 30408848 Free PMC article. Clinical Trial.
-
Thrombosis: Balancing act.Nature. 2014 Nov 27;515(7528):S168-9. doi: 10.1038/515S168a. Nature. 2014. PMID: 25427209 No abstract available.
-
Expression of tissue factor pathway inhibitor by endothelial cells and platelets.Transfus Apher Sci. 2008 Feb;38(1):9-14. doi: 10.1016/j.transci.2007.12.001. Epub 2008 Feb 7. Transfus Apher Sci. 2008. PMID: 18261960 Free PMC article. Review.
-
Thrombin generation assays to personalize treatment in bleeding and thrombotic diseases.Front Cardiovasc Med. 2022 Nov 10;9:1033416. doi: 10.3389/fcvm.2022.1033416. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36440026 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical